ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Current and Emerging Roles of PARP Inhibition in Ovarian Cancer

Michael Birrer, MD, PhD
Published Online:7:40 PM, Wed December 7, 2016

Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, discusses the current and emerging roles of PARP inhibition in ovarian cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.